Biomarin R&D day: massive patient-to-patient variability for Hemo A | SGMO Message Board Posts

Sangamo Therapeutics, Inc.

  SGMO website

SGMO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  136573 of 139043  at  11/17/2019 4:57:24 PM  by

spaddy


 In response to msg 136572 by  civic08801
view thread

Re: Biomarin R&D day: massive patient-to-patient variability for Hemo A

 The "problem" is that BMRN has less adverse effects than Hemlibra..
and not working in every patient is not the same as an adverse effect..
 
In the FDA mind, BMRN drug could be better than current standard of care because it lasts longer than current standard of care and reduces factor consumption and bleeds in even the hardest to treat hemophiliacs..regardless of whether SGMO drug comes out possibly 2 years later and is better..
 
Which is why it will be approved as long as it proves its manufacturing is fine..
 
Reimbursement by insurance and patients wanting to use it, is a completely different story..
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 14     Views: 308
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
136575 Re: Biomarin R&D day: massive patient-to-patient variability for Hemo A civic08801 1 11/17/2019 5:12:23 PM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...